- Life Sciences - 18:00 Novel Antibiotic Resistance gene in Milk
- Medicine - 13:02 Food photos help Instagram users with healthy eating
- Computer Science - 13:00 Opioid abuse drops when doctors check patients’ drug history
- Life Sciences - 11:02 Tick protein helps antibiotics combat MRSA super bug
- Medicine - 11:01 GP job satisfaction falls while the challenges to the sector increase
- Medicine - 11:00 Creative animation empowers pregnant women to voice health concerns
- Social Sciences - 11:00 Decline in serious violence
- Medicine - 10:00 Drones that detect early plant disease could save crops
- Medicine - 08:01 Genomics research progresses from bench to bedside
- Medicine - 08:00 Alcon announces EU launch of CyPass Micro- Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open- angle glaucoma
- Administration - 06:01 Federal budget would win, but the most vulnerable and poor would lose, under capped Medicaid funding scenarios
- Life Sciences - Apr 25 £1.5 million Biological Imaging Centre investment to drive vital cancer & neuroscience research
- Medicine - Apr 25 Imperial part of £100 million Rosalind Franklin Institute
- Medicine - Apr 25 Managing disease spread through accessible modeling
- Medicine - Apr 25 Novel Phage Therapy Saves Patient with Multidrug- Resistant Bacterial Infection
- Medicine - Apr 25 For many women, body image and sex life may suffer after episiotomy
Statins may protect against death from aneurysm, Yale study finds
A study by Yale School of Medicine reveals that survival rates for patients with a thoracic aneurysm are significantly better, and complications are fewer, among patients who take statin cholesterol drugs than those who do not. The study appears in the American Journal of Cardiology.
An aneurysm is a swelling of an artery, and is a common cause of death. It’s usually asymptomatic, with death or a life-threatening complication such as rupture or dissection being the first manifestation. Statins are cholesterol-lowering drugs that are widely used in patients with cardiovascular disease.
Assistant professor of cardiothoracic surgery Ion S. Jovin, M.D., and colleagues studied 649 patients with thoracic aortic aneurysms: 147 were taking statins and 502 were not. In long-term follow-up 80% of those taking statins survived, compared with 67% percent of those not taking statins. In addition, a smaller percentage of those taking statins suffered a rupture or dissection (splitting of the aorta), compared to those who were not taking statins.
"The intake of statins was associated with an improvement in long-term outcomes among these patients," said co-author John Elefteriades, M.D., professor of cardiothoracic surgery at Yale School of Medicine and director of the Aortic Institute at Yale-New Haven Hospital. "In addition to better survival, fewer patients taking statins required surgical intervention," Elefteriades added.
Medical science has searched for decades for a medicine that could treat aneurysm disease, with little success. The current standard therapy is to keep blood pressure low to discourage rupture of the enlarged artery. Jovin said his research suggests that "statins could offer a significant protective effect to patients at risk of death or complications from aneurysm disease. However, the ultimate proof would be a randomized clinical trial." Elefteriades adds, "We now have some arrows in our quiver of medicines to treat this disease."
Other authors are Mona Duggal, Keita Ebisu, Hyung Paek, A. Dana Oprea, Maryann Tranquilli, John Rizzo, Redin Memet, Marina Feldman, James Dziura, and Cynthia A. Brandt of Yale.
Last job offers
- Medicine/Pharmacology - 18.4
Professeur-e ordinaire ou associé-e, médecin-chef-fe du service de médecine interne de réhabilitation...
- Medicine/Pharmacology - 15.4
Chargé-e de cours à 40% dans le domaine neuro-musculaire
- Medicine/Pharmacology - 21.3
Dozentin / Dozenten für Pharmakologie und Pharmatechnologie mit Fachgruppenleitung
- Medicine/Pharmacology - 15.3
Professeur-e ordinaire ou associé-e, médecin adjoint-e agrégé-e
- Medicine/Pharmacology - 25.4
Lecturer in Health Services Management, School of Science and Health
- Medicine/Pharmacology - 25.4
Researcher in epidemiology
- Medicine/Pharmacology - 21.4
Professur (W2) auf Zeit (6 Jahre / tenure track) für Kardiovaskulären Metabolismus
- Medicine/Pharmacology - 11.4
Universitätsprofessur für Gesundheitsökonomie